Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.55 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400770 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL1001473 | 1.00 | MDM4 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL19661184 | 0.92 | TLR2 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL9288118 | 0.91 | KMT2A (0.51) | MDM4TP53CASP3SLC17A5MDM2 | |
| SCHEMBL14432835 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL14788958 | 0.91 | MDM4 (0.59) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL800305 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL1486194 | 0.89 | SLC17A5 (0.58) | MDM4TP53CASP3SLC17A5TLR2 | |
| SCHEMBL4600701 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL800035 | 0.89 | FDFT1 (0.57) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| US-10022422-B2 | Peptidomimetic macrocycles | Alleron Therapeutics, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170296620-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9682123-B2 | Methods of treating metabolic disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-06-20 | — | — | US | disclosed |
| US-9675661-B2 | Bis-sulfhydryl macrocyclization systems | AILERON THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20020048763-A1 | Human genome-derived single exon nucleic acid probes useful for gene expression analysis | AMERSHAM PLC (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002026818-A2 | HUMAN NEDD-1 | AEOMICA, INT. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002008256-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-0509354-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 2000-08-23 | — | — | EP | disclosed |
| US-5442044-A | Hypotensive agents | PFIZER INC. (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0661292-A1 | Orally active renin inhibitors | PFIZER INC. (US) | 1995-07-05 | — | — | EP | disclosed |
| US-5393875-A | Hypotensive, cardiotonic and antiischemic agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0509354-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-21 | — | — | EP | disclosed |
| EP-0438233-A2 | Orally active renin inhibitors | PFIZER INC. (US) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266254-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, CTNNB1, WNT1 | MDM4 190/4885TP53 136/4885CASP3 670/4885 |
| US-20170037105-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | MDM4 3659/4885TP53 1031/4885CASP3 1672/4885 |
| US-20170296620-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | CBS, HLCS, CTH | MDM4 3300/4885TP53 1820/4885CASP3 2522/4885 |
| US-20170212125-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | MDM4 1737/4885TP53 763/4885CASP3 1759/4885 |
| US-20170002042-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | MDM4 1599/4885TP53 542/4885CASP3 1181/4885 |
| US-10022422-B2 | Peptidomimetic macrocycles | HAVCR2, ZC3HAV1, ZC3HAV1L | MDM4 1962/4885TP53 591/4885CASP3 1057/4885 |
| US-20170107252-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | MCL1, BCL2L1, BCL2L11 | MDM4 1093/4885TP53 95/4885CASP3 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.